IDEXX LABORATORIES INC /DE (IDXX) — SEC Financial Statements & Analysis

IDEXX LABORATORIES INC /DE (IDXX) is a in vitro & in vivo diagnostic substances company, incorporated in DE. IDEXX LABORATORIES INC /DE trades on Nasdaq as: IDXX. IDEXX LABORATORIES INC /DE (IDXX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, IDEXX LABORATORIES INC /DE carries a market cap of $41.56B, a P/E ratio of 36.47x, a P/B ratio of 25.78x, a P/S ratio of 9.13x, an enterprise value of $42.34B, and an EV/EBITDA multiple of 26.25x. On profitability, it posts a gross margin of 62.45%, an operating margin of 32.03%, a net margin of 25.03%, a Return on Equity (ROE) of 74.21%, a Return on Assets (ROA) of 33.65%, and a Return on Invested Capital (ROIC) of 47.11%. Per share, it reports EPS of $14.43, diluted EPS of $14.37, free cash flow per share of $15.89, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.77% year-over-year, net income growth of 15.62% year-over-year, and EPS growth of 17.76% year-over-year. On the balance sheet, it maintains a current ratio of 1.17x, a quick ratio of 0.87x, working capital of $221.82M, a debt-to-equity ratio of 1.13x, a debt ratio of 0.53, an interest coverage ratio of 38.60x, free cash flow of $1.25B (TTM), and net debt of $771.93M. Figures sourced from SEC EDGAR.

Market Cap

$41.56B

P/E TTM

36.47x

EPS TTM

$14.43

P/B TTM

25.78x

ROE TTM

74.21%

ROA TTM

33.65%

Debt To Equity

1.13x

Free Cash Flow TTM

$1.25B

Net Revenue TTM Growth 1Y

12.77%

Data as of 2026-06-30 · Source: SEC EDGAR